Abstract:Protein three-dimensional (3D) structure prediction is one of the most challenging issues in the field of computational biochemistry, which has overwhelmed scientists for almost half a century. A significant breakthrough in structural biology has been established by developing the artificial intelligence (AI) system AlphaFold2 (AF2). The AF2 system provides a state-of-the-art prediction of protein structures from nearly all known protein sequences with high accuracy. This study examined the reliability of AF2 models compared to the experimental structures in drug discovery, focusing on one of the most common protein drug-targeted classes known as G protein-coupled receptors (GPCRs) class A. A total of 32 representative protein targets were selected, including experimental structures of X-ray crystallographic and Cryo-EM structures and their corresponding AF2 models. The quality of AF2 models was assessed using different structure validation tools, including the pLDDT score, RMSD value, MolProbity score, percentage of Ramachandran favored, QMEAN Z-score, and QMEANDisCo Global. The molecular docking was performed using the Genetic Optimization for Ligand Docking (GOLD) software. The AF2 models' reliability in virtual drug screening was determined by their ability to predict the ligand binding poses closest to the native binding pose by assessing the Root Mean Square Deviation (RMSD) metric and docking scoring function. The quality of the docking and scoring function was evaluated using the enrichment factor (EF). Furthermore, the capability of using AF2 models in molecular docking to identify hits with key protein–ligand interactions was analyzed. The posing power results showed that the AF2 models successfully predicted ligand binding poses (RMSD < 2 Å). However, they exhibited lower screening power, with average EF values of 2.24, 2.42, and 1.82 for X-ray, Cryo-EM, and AF2 structures, respectively. Moreover, our study revealed that molecular docking using AF2 models can identify competitive inhibitors. In conclusion, this study found that AF2 models provided docking results comparable to experimental structures, particularly for certain GPCR targets, and could potentially significantly impact drug discovery.

Assessment of AI-Based Protein Structure Prediction for the NLRP3 Target

AI-Based Protein Structure Prediction in Drug Discovery: Impacts and Challenges

A Perspective on the Prospective Use of AI in Protein Structure Prediction

Prediction of protein structure and AI

AI-Driven Deep Learning Techniques in Protein Structure Prediction

Artificial intelligence in the prediction of protein–ligand interactions: recent advances and future directions

Protein-ligand binding affinity prediction: Is 3D binding pose needed?

AlphaFold3 versus experimental structures: assessment of the accuracy in ligand-bound G protein-coupled receptors

A Focus on Selected Class A GPCRs

Structure-based, deep-learning models for protein-ligand binding affinity prediction

AI-Augmented Physics-Based Docking for Antibody-Antigen Complex Prediction

AI-Bind: Improving Binding Predictions for Novel Protein Targets and Ligands

The power and pitfalls of AlphaFold2 for structure prediction beyond rigid globular proteins

More than just pattern recognition: Prediction of uncommon protein structure features by AI methods

AlphaFold prediction and analysis of Adhesion-family G protein coupled receptor (aGPCR) structures.

Recent Progress of Protein Tertiary Structure Prediction

AI told you so: navigating protein structure prediction in the era of machine learning

Template‐guided method for protein–ligand complex structure prediction: Application to CASP15 protein–ligand studies

Leveraging nonstructural data to predict structures and affinities of protein-ligand complexes

Leveraging non-structural data to predict structures of protein–ligand complexes

Improving the generalizability of protein-ligand binding predictions with AI-Bind